Aflibercept is a novel, recombinant, fusion protein that consists of portions of vascular endothelial growth factor (VEGF) receptor (R) 1 and VEGFR2 extracellular domains fused to the
INTRODUCTION
Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly in the developed world [1] . As the population ages, AMD has become the most common cause of vision loss [2] . In the United States (US), it affects more than 1.75 million people [3] and is estimated to affect approximately 14 million people worldwide. There are two forms of AMD: the non-neovascular or dry form, which is the most common, and the neovascular or wet form. The wet form of AMD is responsible for the majority of severe vision loss. Choroidal neovascularization (CNV) is the hallmark of neovascular AMD. CNV is characterized by growth of abnormal blood vessels under the macula with disruption of the blood retinal barrier, bleeding, exudation, and eventually scarring.
CNV has been classified into two forms:
classic and occult CNV. The classification scheme was used in early AMD clinical trials.
In classic CNV, the lesions show a welldemarcated appearance with early hyperfluorescence that progressively leaks dye to obscure it's boundaries in late views of the fluorescein angiogram. Occult CNV appears as either late leakage from an undetermined source at the level of the retinal pigment epithelium (RPE) or as ill-defined early leakage with less profuse leakage in late views as in classic CNV. Patients can have 100% classic or occult CNV, but many will have mixed forms of CNV [4] .
The pathogenesis of CNV in the setting of AMD is poorly understood. However, there are currently many reports suggesting that vascular endothelial growth factor (VEGF) plays an essential role [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Animal studies have demonstrated that VEGF over expression in the RPE leads to CNV [15, 16] . In mouse and monkey models of laser-induced CNV, intravitreal injections of an anti-VEGF-A antibody prevented the development of CNV and reduced leakage from pre-existing CNV [17] [18] [19] [20] . Since the establishment of VEGF as an important factor in the development of neovascularization, several drugs have been developed to target this molecule [21] [27] . CATT was a 2-year, multicenter, randomized clinical trial that showed monthly dosing of both medications to be equivalent in terms of BCVA.
Patients treated with ranibizumab gained ?8.5
letters on the ETDRS chart whereas patients treated with bevacizumab gained ?8.0 letters after 1 year of monthly injections.
METHODS
The authors reviewed medical literature using 
INTRODUCTION TO AFLIBERCEPT
Initially, four VEGF trap molecules were constructed [29] . 
CHEMISTRY AND PHARMACOKINETICS
Aflibercept is a soluble fusion protein. It has a molecular weight of 115 kDa and is manufactured from Chinese hamster ovary cells that overexpress the fusion protein.
Aflibercept ophthalmic molecule is identical in structure to the cancer drug, ziv-aflibercept; however, it undergoes a different purification process and the formulation contains different buffer solutions that are less irritating when injected intravitreally. Kd for the predominant VEGF isoform in humans, VEGF165, was 0.5 pM [30] .
Bioavailability following intravenous and subcutaneous dosing was nearly identical [31] .
Following intravitreal administration of aflibercept (2 mg per eye), mean plasma C max for free aflibercept was 0.02 lg/mL and was attained in 1-3 days. The t of aflibercept following intravitreal administration in humans is unknown and the predicted t is based on mathematical models [32, 33] . In rabbits, the intravitreal t of aflibercept is 4.6 versus 3 days for ranibizumab ( 
CLINICAL EFFICACY AND SAFETY

Phase 1/2 Studies
In a phase 1, randomized, double-blind, placebocontrolled trial in 25 patients with subfoveal CNV from AMD, intravenous aflibercept (1.0 or 3.0 mg/ kg) achieved a dose-dependent decrease in retinal thickness on optimal coherence tomography (OCT). However, the study was discontinued due to dose-dependent systemic toxicity, with one patient developing hypertension and another proteinuria [36] . The safety, tolerability, and biological activity of intravitreal VEGF Trap-Eye in the treatment of neovascular AMD were evaluated in the Clinical Evaluation of Antiangiogenesis in the Retina-1 (CLEAR-IT-1) study [37] . During this phase 1 study, 21 patients were Following this initial dosing period, patients Table 1 Pharmacokinetic and pharmacodynamic characteristics of aflibercept [34] • Formulation: intravitreal injection showed that in the aflibercept groups, vision was maintained in 96% of patients receiving 0.5 mg monthly, 95% of patients receiving 2 mg monthly, and 95% of patients receiving 2 mg every 2 months, which was non-inferior and clinically equivalent to the group receiving ranibizumab 0.5 mg monthly, where 94% of patients maintained vision [40] . VIEW 2 results were almost identical. In the aflibercept groups, vision was maintained in 96% of patients receiving aflibercept 0.5 mg monthly, 96% of patients receiving 2 mg monthly, and 96% of was a loading dose of 3 monthly injections followed by dosing every 8 weeks thereafter.
The 2-year results were recently announced by Regeneron Pharmaceuticals, Inc. and showed sustained improvement in visual acuity. During the second year, patients received treatment on an as-required basis, when met specific treatment criteria, but at least one injection every 12 weeks [40] . In an integrated analysis of the VIEW 1 and VIEW 2 studies, the visual acuity gain from baseline in the aflibercept 2 mg every 8 weeks group at week 96 was ?7.6 letters 
